These results suggest that, although in a limited number of cells, the TRIM21 FcR may protect COVID-19 patients on two fronts: conventional virus destruction by proteasomes in adaptive lymphoid and myeloid cells and downregulation of the pathway’s inflammatory branch, preventing an exacerbated inflammatory response. Here, TRIM21 is linked to COVID-19.